NCT05592418 - Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 30, 2023

Primary Completion Date

November 17, 2023

Study Completion Date

November 30, 2023

Conditions

Post COVID-19 ConditionLong COVID

Interventions

DRUG

Rintatolimod

100 to 400 mg twice weekly

OTHER

Placebo / Normal Saline

40 to 160 mL twice weekly

Trial Locations (5)

Alfa Medical Research, Davie

Zenos Clinical Research, Dallas

310 Clinical Research, Inglewood

Hope Clinical Research, Canoga Park

Acclaim Clinical Research, San Diego